VX 10367

Drug Profile

VX 10367

Latest Information Update: 07 May 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chugai Pharmaceutical; Vertex Pharmaceuticals
  • Class Antihyperglycaemics
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 07 May 2003 Discontinued - Preclinical for Type-1 diabetes mellitus (unspecified route)
  • 01 Apr 1997 No-Development-Reported for Type-1 diabetes mellitus (Unknown route)
  • 14 Oct 1994 Preclinical development for Type-1 diabetes mellitus (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top